Neuss, North Rhine-Westphalia, Germany
Over 21 years of experience in the pharmaceutical industry across Johnson & Johnson and UCB, combining deep medical and scientific expertise with strong business acumen and long-standing leadership across multiple therapeutic areas and numerous launches. Shaping strategy, leading transformation, and translating science into portfolio and growth decisions at country and international level. Known for creating clarity, shaping a shared vision, and inspiring high-performing teams to move beyond boundaries and deliver impact. Standing for trust, focus, and authentic leadership, enabling integrated Medical and Commercial value creation.
Reporting to Management Board with full accountability for the Medical organization and Neurology portfolio, including in-market and pipeline assets across Strategy, Evidence and Field Medical Execution, spanning ultra-rare to high-prevalence neurological diseases. • Built and scaled the Medical organization and established a clear multi-layer leadership structure • Led the integration of Rare Diseases and Epilepsy into a unified Neurology organization • Defined and aligned the national Medical, Evidence and Field strategy across in-market and pipeline assets • Established KPI-driven performance management across Medical Affairs • Positioned Germany as pilot country for the global Medical Impact Framework • Elevated Medical to a strategic partner in portfolio and launch decisions
Leading Medical teams across Pulmonary Arterial Hypertension (PAH), Cardiovascular and Specialty Ophthalmology; full responsible for Medical strategy, evidence generation and launch readiness; core member of the Country Value Team. • Drove significant portfolio growth, including +45% increase in treated PAH patients • Successful launch of YUVANCI, the first fixed-dose combination in PAH • Shaped portfolio strategy and lifecycle management in close alignment with Commercial, Access and Global teams • Established a new market segment in Specialty Ophthalmology and advanced pipeline positioning through market readiness strategies • Chaired Medical Affairs Strategic Teams and contributed to global strategies
Leading a Medical team and lifecycle strategy for a 25+ product portfolio across Neuroscience, Oncology, Hematology and Internal Medicine. • Successful line extension of CONCERTA to adult ADHD patients • Developed and established the company-wide Value Optimizers strategy, adopted at EU level • Led lifecycle management and portfolio optimization across a complex multi-TA portfolio • Managed multiple portfolio transitions and divestments, ensuring business continuity and sustained patient access at scale • Ensured patient access for over 800,000 patients across the portfolio
Senior expert in Neuroscience & Respiratory Diseases incl. ADHD, Alzheimer’s, Schizophrenia, Epilepsy and Asthma. Responsible for medical activities and evidence generation. • Successful launch of INUVAIR in asthma • Led local studies and scientific initiatives to support product positioning • Country Representative in international projects